Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Eli Lilly announced that a combination therapy pairing its experimental drug eloralintide with a low dose of tirzepatide demonstrated superior weight loss outcomes compared to tirzepatide monotherapy in a Phase 2 clinical trial. The company presented the findings at a medical conference, marking a significant development in obesity treatment research.
In the 48-week trial, patients receiving the highest dose of the combination regimen achieved average weight loss of 23.3%, equivalent to approxi